Passage Bio (PASG) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting called to order at 9:00 A.M. on May 19, 2026, with introductions of board members and key executives.
Virtual format adopted to increase inclusivity and reach more stockholders.
Agenda included formal business matters followed by a Q&A session.
Board and executive committee updates
Introduction of board members and executive team, including the CFO, legal counsel, and independent accountants.
Shareholder proposals
Four proposals presented: election of two Class III directors, ratification of accounting firm, advisory vote on executive compensation, and advisory vote on frequency of future compensation votes.
No advance notice of alternative director nominations received.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Passage Bio
- Pending merger with Remix is vital as cash dwindles and operations wind down.PASG
Q2 2026 - Merger creates a leading RNA-focused biotech with REM-422 poised for ACC and AML impact.PASG
Investor presentation - Merger forms a biotech leader in RNA-targeted therapies with $100M in new funding.PASG
M&A announcement - Q1 2026 net loss narrowed, but cash shortfall drives strategic review and major cost cuts.PASG
Q1 2026 - PBFT02 gene therapy demonstrated durable biomarker and clinical benefits in FTD-GRN.PASG
Corporate presentation - PBFT02 gene therapy shows durable biomarker response and early disease-modifying potential in FTD-GRN.PASG
Corporate presentation - Virtual annual meeting to vote on directors, auditor, and executive pay proposals.PASG
Proxy filing - Shareholders will vote on directors, auditor, and executive pay, with strong governance and ESG focus.PASG
Proxy filing - Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning.PASG
TD Cowen 46th Annual Health Care Conference